[Mechanisms of metastasis].
Until a primary tumor can successfully produce clinically relevant metastases, the seed cells have to go through a series of stepwise changes (mutations) which have to overcome a sizeable cascade of obstacles. Some of the experimentally proven and clinically suspected changes involve cell surface adhesion, general and local growth factor responsiveness, protease and glycosidase production, motility and deformability. In addition to this tumor cell centered view, one begins to broaden the vision to include changes in the interactions between the tumor cell and its immediate environment. In this context it turns out that the tumor cell seems to learn how to entice neighboring cells and tissues to support its progress with several different responses: extracellular matrix degrading enzymes, growth factors in the target organ, angiogenesis etc. The multitude of phenotype variants is due to genome instability, which is higher in metastatic cells than in primary tumor cells. Recently, it could be shown that even chemotherapy drug resistance is increased in the metastatic organ surrounding (lung) compared to non-metastatic organ targets. The role of the immune system for organ specific metastasis is--if anything--less clear than earlier assumed. Important for the surgeon is the fact that his efforts with the primary tumor could become yet even more successful if the dormant or micrometastases could be abolished. New therapeutic approaches include specific inhibitors of angiogenesis receptors (tyrosine kinase inhibitors). Recently, it was found that continuous low dose chemotherapy together with antiinflammatory agents which block endothelial cell migration and growth prevent not only tumor growth, but abolish micrometastases efficiently in animals. Clinical phase II studies are underway. This, as so many other promising starts in cancer therapy, needs, however, solid confirmation on a very expanded scale before any hopes can be raised.
Burger
M M
MM
max_m.burger@group.novartis.com
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002455:Cell Division; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D018432:Drug Resistance, Multiple; D004359:Drug Therapy, Combination; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008207:Lymphatic Metastasis / Q000517:prevention & control*; D009362:Neoplasm Metastasis / Q000188:drug therapy* / Q000503:physiopathology*; D009366:Neoplasm Seeding; D010641:Phenotype
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000970:Antineoplastic Agents